Naturally Splendid Responds to Health Canada’s Information Request Notice

Vancouver, British Columbia – TheNewswire – October 16, 2020 – Naturally Splendid Enterprises Ltd. (“Naturally Splendid”, “NSE” or “the Company”) (FRANKFURT:50N) (TSXV:NSP) (OTC:NSPDF) has responded through their joint venture Plasm Pharmaceutical (“Plasm”) to Health Canada’s Information Request Notice (“IRN”). The questions as posed by Health Canada are considered a formality as Plasm Pharmaceutical, continues to prepare for aContinue reading “Naturally Splendid Responds to Health Canada’s Information Request Notice”

Naturally Splendid Closes Private Placement, Secures Laboratory Facility

— Naturally Splendid Enterprises Ltd. (“Naturally Splendid”) (TSXV:NSP) (OTC:NSPDF) (Frankfurt:50N) is pleased to announce that it has closed its non-brokered private placement financing for a total of 15,887,503 units (the “Units”) at $0.06 per Unit, for total gross proceeds of $1,053,250 (the “Offering”). Due to oversubscribed demand, the private placement financing was increased from 14,166,667 Units to 17,554,167.Continue reading “Naturally Splendid Closes Private Placement, Secures Laboratory Facility”

Health Canada Requests Protocol Details of COVID-19 Phase 2 Clinical Trial

– TheNewswire – August 10, 2020 — Naturally Splendid Enterprises Ltd. (“Naturally Splendid” or “NSE”) (TSXV:NSP) (OTC:NSPDF) (Frankfurt:50N) advises that subsequent to Heath Canada issuing a No Objection Letter, they have requested specific protocol details regarding the Clinical Trial Application for CavaltinibTM, the target drug of the proposed joint venture with Biologic Pharmaceutical Research, before the trial may commence.Continue reading “Health Canada Requests Protocol Details of COVID-19 Phase 2 Clinical Trial”

Health Canada Grants No Objection Letter to Proceed with COVID-19 Phase 2 Clinical Trial

– July 29, 2020 — Naturally Splendid Enterprises Ltd. (“Naturally Splendid” or “NSE”) (TSXV:NSP) (OTC:NSPDF) (Frankfurt:50N) is pleased to announce that the Company’s phase 2 clinical trial, as per its proposed joint venture with Biologic Pharmamedical Research for Cavaltinib(TM) (See Company news release, May 15, 2020.), has been approved for a COVID-19 clinical trial by Health Canada. The NoContinue reading “Health Canada Grants No Objection Letter to Proceed with COVID-19 Phase 2 Clinical Trial”

Health Canada Requests Clinical Trial Protocol Details

– June 30, 2020 – Naturally Splendid Enterprises Ltd. (“Naturally Splendid”) (TSXV:NSP) (OTC:NSPDF) (Frankfurt:50N) is pleased to provide the following update in regards to the Clinical Trial Application (CTA) to Health Canada submitted May 17, 2020 as a treatment for Covid-19 with the target drug, Cavaltinib(TM). The Company continues to navigate the fast track CTA process withContinue reading “Health Canada Requests Clinical Trial Protocol Details”

Naturally Splendid Provides Clinical Trial Application Update

Naturally Splendid Enterprises Ltd.  (TSXV:NSP) (OTC:NSPDF) (Frankfurt:50N) provides the following update in regards to the Phase 2 Clinical Trial Application with Health Canada for a potential COVID-19 treatment. As an update to the Clinical Trial Application (CTA) process with Health Canada: A CTA was approved for submission to Health Canada on May 17, 2020. The HealthContinue reading “Naturally Splendid Provides Clinical Trial Application Update”

Naturally Splendid – Exciting Times

These are exciting times to be a Naturally Splendid Enterprises Ltd. (“NSE”) shareholder. With the closing of NSE private placement and the Phase II clinical trials for a potential Covid-19 treatment being fast-tracked by Health Canada for Cavaltinibtm, there certainly appear to be bright days ahead. Covid-19 Naturally Splendid has partnered with Biologic Pharmamedical ResearchContinue reading “Naturally Splendid – Exciting Times”

Naturally Splendid Announces Inventory Produced for Target Drug, Cavaltinib(TM) for Phase 2 COVID 19 Clinical Trial

Vancouver, British Columbia – TheNewswire – June 1, 2020 – Naturally Splendid Enterprises Ltd. (“Naturally Splendid”, “NSE” or “the Company”) (FRANKFURT:50N) (TSXV:NSP) (OTC:NSPDF) is pleased to provide the following progress update for a Phase 2 clinical trial treatment for COVID 19. The Company is now awaiting notification by Health Canada to proceed to the Phase 2 clinical trial stage,Continue reading “Naturally Splendid Announces Inventory Produced for Target Drug, Cavaltinib(TM) for Phase 2 COVID 19 Clinical Trial”